Relugolix 120 mg launches in 30-tablet blister packs
Relugolix 120 mg (Orgovyx) is now available in 30-tablet blister packs from UK wholesalers. The new pack format carries PIP code 1295047, giving pharmacy teams a straightforward route to order it through their usual supply chain.
What happened
The manufacturer announced that Orgovyx (relugolix 120 mg), a gonadotrophin-releasing hormone (GnRH) receptor antagonist used in advanced prostate cancer, is now stocked in 30-tablet blister packs. Previously only available in bottle format, the blister presentation gives dispensaries an alternative packaging option. Wholesaler orders go through PIP code 1295047.
Why it matters
Relugolix works differently from the GnRH agonists most pharmacists know well — drugs like leuprorelin or goserelin. Rather than initially causing a testosterone surge before suppression kicks in, relugolix acts as a direct antagonist at the GnRH receptor. That means testosterone suppression begins quickly without the flare effect that can worsen bone pain or urinary symptoms in patients with advanced disease.
For dispensary teams, a change in pack format is more than an admin update. Blister packs can affect how patients manage their medication at home — easier to track missed doses, simpler to carry, more visible at a glance whether a tablet has been taken. For a once-daily oral therapy in a patient group that may be managing several other long-term medicines, that matters.
Pharmacies also need to make sure their PMR system and ordering processes reflect the new PIP code. Using an outdated code or assuming the bottle remains the only available format could cause supply delays or picking errors.
GPhC exam relevance
Relugolix sits in the oncology and urology section of the BNF — an area the GPhC Common Registration Assessment tests through clinical knowledge questions on mechanism of action, monitoring requirements, and drug interactions. GnRH antagonists versus agonists is a comparison worth knowing clearly: how they work, why the distinction matters clinically, and what counselling points differ between them.
The assessment also tests your ability to apply product knowledge in practice settings. Questions may present scenarios where a pharmacy receives a new product, a PIP code changes, or a pack size differs from what a patient usually collects — and ask you to identify the appropriate action. Recognising that a new pack format for an existing drug requires a label check, a dispensing system update, and potentially a patient conversation sits squarely in that territory.
On the counselling side, relugolix has a clinically significant interaction with P-glycoprotein inhibitors and inducers, and strong CYP3A4 inhibitors can also affect exposure. These are the kinds of interactions that appear in assessment questions because they require you to recognise the mechanism, not just recall a list.
What's next
If your pharmacy dispenses relugolix, confirm the new PIP code (1295047) is added to your ordering system. Check whether any standing orders or repeat dispensing arrangements need updating to reflect the pack change. For patients already stabilised on the bottle format, consider whether a quick conversation is needed — the tablet strength is unchanged, but some patients notice packaging differences and may have questions.
More broadly, keep an eye on NHS England and manufacturer communications for any changes to the product's black triangle (▼) status. Orgovyx still carries the inverted triangle, meaning all suspected adverse reactions should be reported via the Yellow Card scheme. That's worth flagging to patients on a new medicine, particularly one in a therapeutic area where side effects — cardiovascular risk, bone density loss, hot flushes — are well documented.
Source: Chemist+Druggist — https://www.chemistanddruggist.co.uk/analysis/orgovyx-relugolix-now-available-in-30-tablet-blister-packs-VAET524F4NBK5HDAPMII4GWIVY/